Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Eris Life Q4 Results: Stock gains 12% as Domestic Branded Formulations leads growth
The management of Eris Lifesciences said the phased rollout of the semaglutide portfolio, including pen-based products and obesity-focused SKUs, is expected to support growth momentum going ahead.
Stocks to buy: Sagar Doshi suggests Varun Beverages, Max Healthcare, Page Industries shares to buy
The Indian stock market saw a marginal rise amid optimism over a potential nuclear deal with Iran. Nifty 50 advanced 0.11%, and the BSE Sensex increased by 0.17%. Despite this, Bank Nifty fell nearly 200 points, while analysts suggested specific stocks to buy.
Vinay Rajani of HDFC Sec suggests Oracle Financial Services, Sun Pharma shares to buy
Indian equity markets experienced a significant selloff on May 18, with Sensex and Nifty 50 dropping over 1%. The BSE Sensex fell over 1,000 points, erasing nearly ₹9 lakh crore in investor wealth amid weak global cues and a bearish trend across sectors.
Selling at higher levels turns 23,800 into key barrier for Nifty: Analysts
Benchmark Nifty closed lower last week. Analysts anticipate continued range-bound trading for Nifty this week. Trading strategies suggest buying on dips and selling on rallies within the 23,800-23,200 range. Specific stock recommendations include Indus Towers, Samvardhana Motherson International, Aditya Birla Capital, Sun Pharmaceutical Industries, and Arvind Limited. Investors are advised to consider these opportunities.
Aditya Birla Group to invest $500 million in Vodafone Idea as revival signal strengthens
Aditya Birla Group is injecting ₹4,730 crore into Vodafone Idea (Vi) through a preferential allotment, bolstering the telecom operator's financial standing. This capital infusion follows Kumar Mangalam Birla's return as chairman and aims to support Vi's efforts to compete with rivals Reliance Jio and Bharti Airtel.
Market Trading Guide: Buy Zydus Lifesciences, Solar Industries on Friday for gains up to 15%
Nifty 50 closed higher for a second straight session, driven by banking, metal and pharma stocks despite IT weakness. Analysts see 23,800 as a crucial resistance level, while recommending Zydus Lifesciences and Solar Industries India for near-term gains on strong technical indicators and bullish momentum.
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition
Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. The stock also gained momentum as Zydus announced a $166 million acquisition of US-based Assertio. Investor sentiment improved on expectations of capital return and strategic business expansion.
Cipla soars 8% despite disappointing Q4; what's driving pharma stock?
Going forward Cipla's management expects to pick up momentum in FY27 and aspires $1 billion revenue from the US itself.
Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata Motors
Indian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL, Tata Motors, and Bharti Airtel are in focus due to quarterly results and news developments. Zydus Lifesciences is nearing a US acquisition, while Maruti Suzuki commits to green logistics.
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India, Europe, and emerging markets show healthy growth. New launches like Semaglutide and Abatacept are expected to drive future expansion. Margins are set to improve with better product mix and cost controls.
Vodafone Idea and 4 other midcap stocks hit 52-week highs, rally up to 40% in a month
Benchmark indices ended marginally higher as five BSE 150 Midcap stocks touched fresh 52-week highs, reflecting strong investor sentiment and bullish momentum. Vodafone Idea, SAIL, MCX, Laurus Labs and Ajanta Pharma recorded notable monthly gains, signalling sustained buying interest despite subdued broader market performance overall.
Neuland Laboratories shares rally 7% as profit jumps seven-fold and revenue doubles in Q4
Neuland Laboratories shares saw a significant jump following a strong Q4 performance. The company reported a massive increase in profit and revenue year-on-year. This robust financial result was driven by strong business momentum across key segments. The company is also investing in future growth through strategic initiatives.